Latest Healthcare It News

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Sigma Healthcare has achieved unanimous shareholder approval for its proposed merger with Chemist Warehouse, marking a pivotal step toward reshaping Australia's pharmaceutical retail landscape. The merger now awaits final court approval, with implementation anticipated in mid-February 2025.

Sigma Healthcare has successfully passed all key resolutions at its extraordinary general meeting, clearing a major hurdle for its proposed merger with Chemist Warehouse. The deal now awaits final court approval, with implementation expected in February.